自研“自愈合”生物材料技术，这家深圳初创企业完成数千万元A+轮融资

Core Insights - Shenzhen Huano Biotechnology Co., Ltd. has completed an A+ round of financing led by Guozhong Capital, with funds primarily allocated for expanding its product pipeline based on its self-healing supramolecular technology platform and upgrading the production capacity of core products [1][4] Group 1: Company Overview - Huano Biotechnology innovatively applies "self-healing supramolecular" technology to develop injectable and moldable fluid implant materials, with its first Class III medical device product, "Colloidose® absorbable hemostatic fluid gelatin," expected to receive approval from the National Medical Products Administration in October 2024 [1][3] - The company was founded in December 2017 by a team led by a Harvard University PhD and is recognized as a national high-tech enterprise, boasting over 20 years of experience in the biomaterials industry and having published more than 100 research papers in top academic journals [3] Group 2: Product and Market Position - The hemostatic fluid gelatin product is widely used in non-compressible tissue wounds (such as brain and spine) and minimally invasive surgical hemostasis, with the global market dominated by Johnson & Johnson and Baxter's fluid gelatin products [3] - Huano's self-developed "self-healing supramolecular" technology offers a new route for fluid gelatin, enhancing mechanical properties while maintaining minimally invasive injection characteristics, achieving rapid gel solidification and physical sealing of bleeding points with reduced dosage and faster degradation [3] Group 3: Future Prospects - Guozhong Capital's investment team indicates that Huano Biotechnology has achieved domestic supply chain localization for high-end hemostatic materials and has full control over the production process, suggesting potential for extending this technology platform to develop and apply more innovative medical consumables in the future [4]